Sacituzumab govitecan-hziy

STARt-002 is the first clinical study to combine a Vβ6-selective T-cell agonist with an ADC, pairing invikafusp alfa's selective T-cell activation with TRODELVY's TROP2-directed delivery of a cytotoxic payload Oral presentation will feature interim clinical results from two distinct metastatic breast cancer populations, triple-negative and HR-positive/HER2-negative, building on initial results presented at AACR 2026 CAMBRIDGE, Mass., Oct. 2, 2026 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapies for oncology and inflammation and immunology (I&I), today announced that interim results from the STARt-002 clinical study have been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting, taking place November 4–8, 2026, in Phoenix, Arizona. "Invikafusp alfa is designed for antigen-rich tumors. ADCs like TRODELVY help create that state by releasing tumor antigens and inflaming the tumor microenvironment, priming less immunogenic tumors for T-cell-mediated responses," said Kevin Chin, M.D., Chief Medical Officer of Marengo Therapeutics. "STARt-002 is the first clinical study to test this hypothesis by pairing a selective T-cell agonist with an ADC, and this combination could extend invikafusp alfa's reach beyond tumors that are antigen-rich on their own. Triple-negative and HR-positive/HER2-negative metastatic breast cancer are two settings where patients still have limited options after standard therapies. We look forward to presenting interim results from both cohorts at SITC." STARt-002 is the company's Phase 1b/2 trial evaluating invikafusp alfa in combination with TRODELVY® (sacituzumab govitecan-hziy) in patients with metastatic breast cancer. The Phase 2 portion is evaluating two distinct patient populations: metastatic triple-negative breast cancer (TNBC) and HR-positive/HER2-negative metastatic breast cancer. Following completion of the safety lead-in, both expansion cohorts are enrolling at the recommended Phase 2 dose at select cancer centers across North America. The SITC presentation will feature interim results from both expansion cohorts, and Marengo expects to report additional data in 2027. The STARt-002 combination strategy reflects invikafusp alfa's long-term potential as an immuno-oncology backbone and builds on STARt-001, a Phase 1/2 trial evaluating invikafusp alfa monotherapy in patients with PD-1-resistant, biomarker-enriched solid tumors, including TNBC. Updated STARt-001 results will be presented during an oral presentation at the European Society for Medical Oncology (ESMO) 2026 Congress, taking place October 23–27 in Madrid, Spain. Presentation Details Title: Initial clinical results from START-002: A Phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triple-negative or HR+/HER2- mBC Abstract Number: 514 Session: Oral Abstract Session 3 Date/Time: Saturday, November 7, 2026 3:30PM MT Presenter: Steven Isakoff, MD, PhD, MMSc; Mass General Brigham About Marengo Therapeutics Marengo Therapeutics, Inc., a clinical-stage biotech company, develops novel TCR-targeting antibodies that selectively modulate common and disease-specific T-cell subsets of the germline TCR repertoire to provide durable protection against cancer and autoimmune diseases. With a passionate team of dedicated scientists experienced in immunology and oncology, and three proprietary platforms, Selective T Cell Activation Repertoire (STAR), Trispecific T Cell Engager (TriSTAR) and T Cell Depletor (MSTAR), Marengo is working to selectively target the right T cells in the right patients to create a world in which everyone's immune system can defeat cancer and autoimmune diseases. To learn more, visit marengotx.com. About Invikafusp Alfa (STAR0602) Invikafusp alfa (STAR0602) is the lead candidate from Marengo's STAR™ platform and a first-in-class, bispecific dual T-cell agonist. It is designed to selectively activate Vβ6 T cells, a common T-cell subset present across many tumor types, by combining a non-clonal mode of TCR activation with a T-cell co-stimulatory signal in a single molecule. This approach promotes the expansion of clonally diverse, effector memory Vβ6 T cells, with the goal of enhancing and sustaining antitumor immunity. Invikafusp alfa was designed to restore and amplify antitumor immunity in patients who have progressed on, or are insensitive to, prior immune checkpoint blockade. About the STARt-002 Clinical Study STARt-002 (NCT06827613) is a Phase 1b/2, open-label, multicenter study investigating the combination of invikafusp alfa and TRODELVY® in patients with unresectable, locally advanced or metastatic breast cancer. The trial consists of a safety lead-in phase followed by two dose-expansion cohorts: one in metastatic TNBC and one in HR-positive/HER2-negative metastatic breast cancer. More information is available at clinicaltrials.gov. TRODELVY® is a registered trademark of Gilead Sciences, Inc. Marengo Contacts: Media | Peg Rusconi | [email protected] Investors | [email protected] SOURCE Marengo Therapeutics 21% more press release views with Request a Demo

Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports. Akeso and Summit Therapeutics' ivonescimab, B7-H3 antibody-drug conjugates and a surprise negative overall survival trend from Enhertu headlined WCLC26. Plus more. 1. US weighs allowing most pharma licensing deals with China, sources say (Reuters) The U.S. Treasury Department is working on rules that would allow most licensing deals for Chinese drugs, Reuters reports, citing three people who have been briefed on the process. The rules are likely to allow U.S. companies to continue buying new drug candidates from Chinese companies as long as they are not related to pathogens or technologies that could be weaponized, the sources reportedly told Reuters. Lawmakers hawkish on China have asked the Treasury to crack down on biopharma transactions with China under the COINS Act. 2. Akeso, Summit’s ivonescimab tops Keytruda in lung cancer survival, with strong data in PD-L1-high patients Ivonescimab’s detailed head-to-head overall survival win against Keytruda revealed a 27% benefit in first-line, PD-L1-positive non-small cell lung cancer in the China phase 3 Harmoni-2 trial. The Akeso-Summit PD-1xVEGF bispecific prolonged median OS by 8.2 months to 30.8 months. The drug showed especially strong results in PD-L1-high patients, lowering the risk of death by 42% versus Merck’s PD-1 inhibitor. 3. GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival The B7-H3 antibody-drug conjugate race is heating up among Chinese assets licensed to Big Pharma. GSK’s Hansoh-partnered ris-rez achieved a median OS of 18.5 months in a China phase 3 small cell lung cancer trial in previously treated patients. Roche’s partner MediLink reported a median OS of 12 months for their candidate, tam-peli, in a separate second-line SCLC trial in China. Cross-trial comparisons should be viewed with caution. 4. Increased deaths shadow AstraZeneca, Daiichi’s Enhertu first-line lung cancer data In a rare setback for AstraZeneca and Daiichi Sankyo’s Enhertu, the star HER2 ADC showed a negative OS trend against Keytruda plus chemotherapy in first-line, HER2-mutant NSCLC. While the phase 3 Destiny-Lung04 trial met its progression-free survival endpoint, an interim OS analysis found that patients in the Enhertu arm lived a median 29.3 months, versus 33.1 months in the control arm. 5. Legend Biotech names Novartis veteran Ingrid Zhang as new CEO Legend Biotech has named Novartis’ former China head, Ingrid Zhang, as its new CEO. Zhang, who most recently served as chief commercial officer for Novartis’ ex-U.S. business, succeeded interim chief Alan Bash, who has resumed his role as president of Carvykti. In a LinkedIn post shortly before the announcement, Zhang said patient access has “shaped how I’ve led.” 6. GSK doubles down on Chimagen with $750M multiple myeloma wager GSK licensed a trispecific T-cell engager from China’s Chimagen Biosciences for up to $750 million. The disease is multiple myeloma, but the three targets were not disclosed. The program is expected to enter clinical testing in 2027. 7. Merck, Gilead’s failed Trodelvy lung cancer trial shows better China results 8. BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout 9. Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer 10. BMS, Ono take Amgen to task as FDA's Opdivo biosimilar decision looms 11. SK pens $315M pact with fellow South Korean company for Parkinson’s prospect 12. AZ, Daiichi's Enhertu scores long-awaited NICE blessing in HER2-low breast cancer